Home > Historical Performance > Historical Transaction Report

Transaction Details

Company: MiMedx Group
Ticker:MDXG
Yahoo Beta:0.33
Industry:Medical appliances & equipment

Company Description:  MiMedx develops therapeutic treatments using human placental tissue.

Purchase Date:26 Jan 2018 Sale Date:29 Sep 2021
Purchase Price:$15.85 Sale Price:$6.15
  --Split Adjusted:$15.85  --Split Adjusted:$6.15
Shares Purchased:350 Shares Sold:350
  --Split Adjusted:350  --Split Adjusted:350
Transaction Fee:$6.95 Transaction Fee:$0.06
Price Range (6 Months Prior):    Price Range (6 Months After):    
High$17.34 High$0.00
Date22 Aug 2017 Date01 Jan 1996
Low$10.87 Low$0.00
Date22 Nov 2017 Date01 Jan 1996
S&P (Purchase Date):$2,850.95 S&P (Sale Date):$4,383.25

Purchase
Timing:  We bought near the six month high after the stock gained over 10% in the last week.
Reason:  MiMedx is developing a new product line in the area of pain management. The opioid crisis has made demand for non-opioid pain treatments attractive. The expanded suite of products should increase sales force efficiency leading to improved margins. We believe the market is overreacting to a lawsuit and heavy short sales, leading to an attractive entry point. The company has beat guidance in 27 of the last 28 quarters. The company's current products serve the diabetic market, which is growing as type II diabetes rises with an aging and increasingly obese population.

Sale
Timing:  x
Reason:  While we believe MDXG's core product is a good one, the company continues to have issues. The stock recently plummeted after clinical trials for two possible extensions of the company's products failed. We lack confidence in the company's governance.

S&P Gain: 53.75 % Annualized Gain: 12.73%
Stock Gain: -61.2 % Annualized Gain: -23.19%

Dividends:$0.00
Net Holding Return ($): $-3,402.01
Net Holding Return (%): -61.25 %